Has Benjamin McGrath, DPM received payments from drug or device companies?

Yes. Drug and device makers reported $25,013 in general payments to Benjamin McGrath, DPM across 401 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Benjamin McGrath, DPM did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Benjamin McGrath, DPM come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Benjamin McGrath, DPM

Podiatrist · Los Angeles, CANPI 1851805204

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.8%), education and travel and lodging — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Arthrex at 31.7% of the total. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,013in general payments, 2019–2025

Across 401 payments — averaging $62.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Arthrex$8K
Paragon 28, Inc.$2K
Biotissue Holdings Inc.$2K
Empire Medical, Inc$2K
Stryker$2K
Smith+Nephew$2K
plus $7K from 45 others

What the payments were for

Travel & lodging$5,86823%
Food & beverage$11,20845%
Education$7,93632%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Arthrex	35	$7,922
Paragon 28, Inc.	12	$2,371
Biotissue Holdings Inc.	19	$2,246
Empire Medical, Inc	3	$1,867
Stryker	20	$1,729
Smith+Nephew	113	$1,623
Vilex LLC	11	$1,130
Sportstek Medical, Inc	1	$640
Integra Lifesciences Corporation	16	$580
Paratek Pharmaceuticals, Inc.	24	$530
Linvatec Corporation	2	$472
GRT US Holding, Inc.	12	$385
Amgen	27	$318
Orthofix Medical, Inc.	3	$318
AbbVie(2 entities)	17	$312
Averitas Pharma Inc.	7	$189
In2bones USA, LLC	2	$172
La Jolla Pharmaceutical Company	7	$170
Amniox Medical, Inc.	4	$159
Surgenex LLC	1	$147
Cumberland Pharmaceuticals, Inc.	4	$141
Treace Medical Concepts, Inc.	1	$135
Melinta Therapeutics, LLC	6	$120
Derma Sciences, Inc.	1	$109
Tactile Systems Technology Inc	5	$101
Bioventus LLC	5	$100
Ferring Pharmaceuticals Inc.	1	$80
Merck	4	$78
Janssen Scientific Affairs, LLC	1	$77
Inari Medical, Inc.	2	$59
Zimmer Biomet	2	$58
DJO, LLC	2	$58
Acera Surgical, Inc.	2	$57
Zyla Life Sciences, Inc.	4	$53
Mimedx Group, Inc.	2	$52
Medtronic	2	$45
Assertio Therapeutics, Inc.	3	$41
Johnson & Johnson(2 entities)	2	$38
Theratechnologies Inc.	2	$38
Alfasigma USA, Inc.	2	$31
Viiv Healthcare Company	1	$31
Organogenesis Inc.	2	$31
Aroa Biosurgery Incorporated	1	$31
Davol Inc.	1	$30
Medline Industries LP	1	$29
Arteriocyte Medical Systems, Inc.	1	$28
Tetraphase Pharmaceuticals, Inc.	1	$24
Saxum Surgical, Inc.	1	$17
Abbott	1	$17
Pfizer	1	$12
Acell, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,013 in reported general payments places this provider in the 95th percentile of 721 podiatrist providers in California.

See all podiatrist providers in California →

Medicare billing

Part B allowed, 2024

$140,557

Medicare patients

194

Services billed

1,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ciclopirox	81	$1,448
Ketoconazole	29	$739
Doxycycline Hyclate	23	$248
Terbinafine Hcl	17	$225
Cephalexin	22	$138
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	24	$95
Mupirocin	12	$54
Gabapentin	11	$31

Paid to pharmacies, not to this prescriber.

Other podiatrist in Los Angeles

David ArmstrongLos Angeles$695K
Charles AnanianLos Angeles$69K
Edward KimLos Angeles$48K
Laura ShinLos Angeles$20K
Renato SousaLos Angeles$14K
Megan IshibashiLos Angeles$10K
Shannon RushPleasanton$1.9M
Babak BaravarianSanta Monica$1.1M
Robert KleimanCalexico$913K
Bruce LawrenceOceanside$810K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →